BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20631501)

  • 1. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas.
    Chan WK; Au WY; Wong CY; Liang R; Leung AY; Kwong YL; Khong PL
    Clin Nucl Med; 2010 Aug; 35(8):571-5. PubMed ID: 20631501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
    Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
    Khong PL; Pang CB; Liang R; Kwong YL; Au WY
    Ann Hematol; 2008 Aug; 87(8):613-21. PubMed ID: 18509641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype].
    Zhang J; Wang R; Fan Y; Fu Z; Zhang X; Liao X; Liu M; Kang L; Cui Y; Wang Y; Jiang Q
    Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(33):2576-9. PubMed ID: 25511487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
    Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
    J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
    Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
    Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
    Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
    World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
    Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
    J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
    Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
    Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
    Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in T-cell and NK-cell neoplasms.
    Kako S; Izutsu K; Ota Y; Minatani Y; Sugaya M; Momose T; Ohtomo K; Kanda Y; Chiba S; Motokura T; Kurokawa M
    Ann Oncol; 2007 Oct; 18(10):1685-90. PubMed ID: 17716987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
    Cahu X; Bodet-Milin C; Brissot E; Maisonneuve H; Houot R; Morineau N; Solal-Celigny P; Godmer P; Gastinne T; Moreau P; Moreau A; Lamy T; Kraber-Bodere F; Le Gouill S
    Ann Oncol; 2011 Mar; 22(3):705-711. PubMed ID: 20739714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptionally low metabolic activity in aggressive peripheral T-cell lymphoma.
    Tang B; Douglas-Nikitin V; Balon H; Wong CO; Khong PL; Wong CY
    Nucl Med Commun; 2009 Nov; 30(11):838-40. PubMed ID: 19734816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of T-cell lymphomas by FDG PET/CT.
    Feeney J; Horwitz S; Gönen M; Schöder H
    AJR Am J Roentgenol; 2010 Aug; 195(2):333-40. PubMed ID: 20651187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.
    Karam M; Novak L; Cyriac J; Ali A; Nazeer T; Nugent F
    Cancer; 2006 Jul; 107(1):175-83. PubMed ID: 16721817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.